335 related articles for article (PubMed ID: 35254622)
1. A Narrative Review of Pathogenetic and Histopathologic Aspects, Epidemiology, Classification Systems, and Disease Outcome Measures in Systemic Sclerosis.
Lazzaroni MG; Piantoni S; Angeli F; Bertocchi S; Franceschini F; Airò P
Clin Rev Allergy Immunol; 2023 Jun; 64(3):358-377. PubMed ID: 35254622
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Clinical Trial Design Issues in Systemic Sclerosis: an Update.
Gordon JK; Domsic RT
Curr Rheumatol Rep; 2016 Jun; 18(6):38. PubMed ID: 27146381
[TBL] [Abstract][Full Text] [Related]
4. Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis.
Ingegnoli F; Ughi N; Mihai C
Best Pract Res Clin Rheumatol; 2018 Apr; 32(2):223-240. PubMed ID: 30527428
[TBL] [Abstract][Full Text] [Related]
5. Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.
Zhao M; Wu J; Wu H; Sawalha AH; Lu Q
Clin Rev Allergy Immunol; 2022 Apr; 62(2):273-291. PubMed ID: 33449302
[TBL] [Abstract][Full Text] [Related]
6. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
7. Scleroderma epidemiology update.
Calderon LM; Pope JE
Curr Opin Rheumatol; 2021 Mar; 33(2):122-127. PubMed ID: 33481429
[TBL] [Abstract][Full Text] [Related]
8. An update on recent randomized clinical trials in systemic sclerosis.
Boleto G; Avouac J; Allanore Y
Joint Bone Spine; 2021 Oct; 88(5):105184. PubMed ID: 33887472
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and risk factors for pulmonary hypertension in systemic sclerosis.
Yaqub A; Chung L
Curr Rheumatol Rep; 2013 Jan; 15(1):302. PubMed ID: 23292818
[TBL] [Abstract][Full Text] [Related]
10. Systemic sclerosis sine scleroderma.
Kucharz EJ; Kopeć-Mędrek M
Adv Clin Exp Med; 2017 Aug; 26(5):875-880. PubMed ID: 29068586
[TBL] [Abstract][Full Text] [Related]
11. Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment.
Affandi AJ; Radstake TR; Marut W
Semin Immunopathol; 2015 Sep; 37(5):475-87. PubMed ID: 26168983
[TBL] [Abstract][Full Text] [Related]
12. [Systemic sclerosis - diagnosis and classification].
Genth E; Krieg T
Z Rheumatol; 2006 Jul; 65(4):268-74. PubMed ID: 16804700
[TBL] [Abstract][Full Text] [Related]
13. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status.
Simeón-Aznar CP; Fonollosa-Plá V; Tolosa-Vilella C; Espinosa-Garriga G; Ramos-Casals M; Campillo-Grau M; García-Hernández FJ; Castillo-Palma MJ; Sánchez-Román J; Callejas-Rubio JL; Ortego-Centeno N; Egurbide-Arberas MV; Trapiellla-Martínez L; Gallego-Villalobos M; Sáez-Comet L; Velilla-Marco J; Camps-García MT; de Ramón-Garrido E; Esteban Marcos EM; Pallarés-Ferreres L; Hidalgo-Tenorio C; Sabio-Sánchez JM; Gómez-de la Torre R; Salvador-Cervello G; Rios-Blanco JJ; Gil-Aguado A; Vilardell-Tarrés M
Semin Arthritis Rheum; 2012 Jun; 41(6):789-800. PubMed ID: 22169458
[TBL] [Abstract][Full Text] [Related]
14. Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis.
Nihtyanova SI; Sari A; Harvey JC; Leslie A; Derrett-Smith EC; Fonseca C; Ong VH; Denton CP
Arthritis Rheumatol; 2020 Mar; 72(3):465-476. PubMed ID: 31682743
[TBL] [Abstract][Full Text] [Related]
15. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
[TBL] [Abstract][Full Text] [Related]
17. Current Trends in Vascular Biomarkers for Systemic Sclerosis: A Narrative Review.
Fioretto BS; Rosa I; Matucci-Cerinic M; Romano E; Manetti M
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835506
[TBL] [Abstract][Full Text] [Related]
18. The concept of early systemic sclerosis following 2013 ACR\EULAR criteria for the classification of systemic sclerosis.
Valentini G; Marcoccia A; Cuomo G; Iudici M; Vettori S
Curr Rheumatol Rev; 2014; 10(1):38-44. PubMed ID: 24720644
[TBL] [Abstract][Full Text] [Related]
19. Early systemic sclerosis-opportunities for treatment.
Sakkas LI; Simopoulou T; Katsiari C; Bogdanos D; Chikanza IC
Clin Rheumatol; 2015 Aug; 34(8):1327-31. PubMed ID: 25711876
[TBL] [Abstract][Full Text] [Related]
20. Very early and early systemic sclerosis in the Spanish scleroderma Registry (RESCLE) cohort.
Trapiella-Martínez L; Díaz-López JB; Caminal-Montero L; Tolosa-Vilella C; Guillén-Del Castillo A; Colunga-Argüelles D; Rubio-Rivas M; Iniesta-Arandia N; Castillo-Palma MJ; Sáez-Comet L; Egurbide-Arberas MV; Ortego-Centeno N; Freire M; Vargas-Hitos JA; Ríos-Blanco JJ; Todolí-Parra JA; Rodríguez-Carballeira M; Marín-Ballvé A; Chamorro-Fernández AJ; Pla-Salas X; Madroñero-Vuelta AB; Ruiz-Muñóz M; Fonollosa-Pla V; Simeón-Aznar CP;
Autoimmun Rev; 2017 Aug; 16(8):796-802. PubMed ID: 28564618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
